J&J’s Spravato Wins FDA OK as Monotherapy for Depression
Johnson & Johnson has received Food and Drug Administration approval to use its Spravato nasal spray as a standalone treatment for adults with major depressive disorder who have shown an inadequate response to at least two oral antidepressants. This marks the first time a medication of this type has been approved in its sole form … Read more